Search

Search Constraints

You searched for: Author/Creator Musuraca, G.

Search Results

1. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019)

2. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019)

3. DEVEC: A PHASE II STUDY OF METRONOMIC CHEMOTHERAPY IN ELDERLY NON‐FIT PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS (PROMOTED BY FIL). (June 2017)

4. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL). (12th June 2019)

5. OBINUTUZUMAB‐MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. (June 2017)

6. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL. (23rd June 2022)

7. P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. (23rd June 2022)

8. P992: OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION. (23rd June 2022)